LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Затворен

СекторЗдравеопазване

52.37 2.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

52.3

Максимум

52.57

Ключови измерители
By Trading Economics
Приходи	882M 2.2B
Продажби	-47M 12B
P/E Средно за сектора	17.397 77.671
EPS	1.46
Дивидентна доходност	4.76
Марж на печалбата	17.959
Служители	34,100
EBITDA	1.3B 4.6B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+1.68% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	4.76% 2.35%
Следваща дата на дивидент	2.02.2026 г.
Следваща дата на екс-дивидент	2.01.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	16B 105B
Предишно отваряне	49.98
Предишно затваряне	52.37

Настроения в новините

By Acuity

38%

62%

109 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

N/A / 50.57 Подкрепа & съпротива

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.10.2025 г., 11:14 ч. UTC

Печалби

Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance

10.10.2025 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

12.12.2025 г., 15:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 13:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Broadcom, Oracle, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 11:52 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Broadcom, Oracle, Lululemon, Costco, Netskope, and More -- Barrons.com

20.11.2025 г., 13:00 ч. UTC

Печалби

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy. -- Barrons.com

6.11.2025 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. -- Barrons.com

30.10.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30.10.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30.10.2025 г., 11:32 ч. UTC

Печалби

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Legacy Portfolio >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of 80c Loss Per Shr Net Impact Related to Acquired IPRD Charges and Licensing Income >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q Adjusted Gross Margin 72.9% >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: 3Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q Gross Margin 71.9% >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 20c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q Rev $12.22B >BMY

30.10.2025 г., 10:59 ч. UTC

Печалби

Bristol Myers Squibb 3Q EPS $1.08 >BMY

10.10.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10.10.2025 г., 11:02 ч. UTC

Придобивния, сливания и поглъщания

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10.10.2025 г., 11:01 ч. UTC

Придобивния, сливания и поглъщания

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4.08.2025 г., 11:59 ч. UTC

Печалби

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

1.68% нагоре

12-месечна прогноза

Среден 53.29 USD 1.68%

Висок 68 USD

Нисък 37 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 50.57Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

109 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.